Baidu
map

盘点:2018年2月Gut研究精选

2018-02-01 zhangfan MedSci原创

Gut

2018年2月Gut研究精选



【1】微生物失调检测可区分胃炎和胃癌


幽门螺旋杆菌是引起胃癌的原因之一。慢性幽门螺旋杆菌的感染会导致体内酸分泌的减少,这可能会引起胃细菌群体生长异常。微生物组的这种变化可能会增加对胃粘膜的攻击性,并进一步导致恶性肿瘤。来自波尔图大学的研究人员研究了胃微生物群体与慢性胃炎和胃癌之间的关系。

研究人员招募了54例胃癌患者和81例慢性胃炎患者,并使用新一代测序技术对其16S rRNA基因谱进行回顾性分析。研究人员使用线性判别分析效应大小来评估两个患者组的微生物组成差异。最相关的分类群与临床诊断之间的关联通过实时定量PCR进行验证。研究人员还使用PICRUSt获得了微生物群落的预测功能分析。

研究人员发现,胃癌患者的微生物多样性降低,螺杆菌丰度下降,其他细菌属富集,主要以肠道共生菌为代表。将这些类群与微生物生态失调指数结合分析发现,生态失调具有极好的区分胃炎和胃癌的能力。微生物群的功能特征分析与在癌症中存在亚硝化微生物群体相一致。主要观察结果在来自不同地理位置的队列研究中得到证实。

【2】英利昔单抗对激素耐受性急性重症溃疡性结肠炎长期治疗效果优于环孢素


环孢素和英利昔单抗对于激素耐受性急性重症溃疡性结肠炎(ASUC)二线短期疗效相似。近日研究人员比较了二者的长期ASUC治疗效果。

115名ASUC患者接受环孢素或英利昔单抗联合硫唑嘌呤治疗,评估治疗1或5年无结肠切除术生存率。

随访5.4年后,环孢素1或5年的无结肠切除术生存率分别为70.9%,61.5%;英利昔单抗为69.15%,65.1%。初始环孢素治疗后1或5年接受英利昔单抗治疗率为45.7% 和 57.1%,仅4名接受英利昔单抗治疗患者转为接受环孢素治疗。

【3】内脏敏感性与功能性肠胃炎疾病程度正相关


近日研究人员评估了功能性肠胃炎患者内脏敏感性与疾病严重程度之间的关系。

总计1144名功能性肠胃炎或肠易激综合征患者参与研究,接受气囊扩张法胃底、降结肠或直肠内脏敏感性测试,并通过问卷调查评估功能性肠胃炎症状严重程度、非功能性肠胃炎躯体症状、焦虑和抑郁。

研究发现,随着内脏敏感性增加,胃肠道症状的严重程度逐渐增加,但敏感性梯度与症状严重程度 (η2:0.047-0.11)和焦虑抑郁程度(p<0.05)存在有显著性差异。

【4】Chk2激活导致肝细胞癌进展


近日研究人员使用二乙基亚硝胺诱导HCC动物模型评估了DNA损伤反应蛋白检查点激酶2(Chk2)的表达。Chk2同时也在两个人类肝癌样本队列中确定。为了评估Chk2的功能作用,通过使用hTERT基因(HuS)永生化的HCT116,Huh7和人肝细胞进行增益和功能丧失、诱变、核型分析和免疫荧光/活体成像。

研究证明HCC肿瘤发生过程中有丝分裂错误导致染色体/ DNA损伤和Chk2的激活。Chk2有丝分裂纺锤体内的过度表达/磷酸化和错位定位有助于诱导滞育染色体。Chk2敲除可以逆转染色体滞后和有丝分裂活性。此外,Chk2上调与Aurora B激酶相互作用增加有丝分裂活性,导致染色体凝聚和胞质分裂。Chk2叉头相关结构域是有丝分裂结构错位定位所必需的。此外,视网膜母细胞瘤蛋白磷酸化会导致有丝分裂发生缺陷。

【5】核苷酸类抗HBV药物可提高患者IFN-λ3水平


白细胞介素-28b基因编码干扰素(IFN)-λ3基因多态性在慢性丙型肝炎患者的治疗过程中具有临床意义。近日研究人员考察了IFN-λ3水平与HBV抗病毒药物之间的关系。

254名HBV患者接受血浆IFN-λ3检测后发现,接受核苷酸类药物,如阿德福韦或替诺福韦,其IFN-λ3水平高于接受核苷类药物(拉米夫定或恩替卡韦)的患者,接受核苷酸类抗HBV药物后IFN-λ3水平上升。细胞模型中,阿德福韦处理后细胞培养液,与恩替卡韦相比,能显著诱导干扰素刺激基因(ISGS)的产生,抑制乙肝表面抗原(HBsAg)产生。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=286862, encodeId=abfe28686268, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:53 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285561, encodeId=f8f028556102, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:04 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284415, encodeId=269d284415ca, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:15 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284176, encodeId=f9252841e60d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:30:03 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284173, encodeId=07742841e317, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:28:54 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-10 天涯183

    非常好的文章.学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=286862, encodeId=abfe28686268, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:53 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285561, encodeId=f8f028556102, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:04 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284415, encodeId=269d284415ca, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:15 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284176, encodeId=f9252841e60d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:30:03 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284173, encodeId=07742841e317, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:28:54 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-06 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=286862, encodeId=abfe28686268, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:53 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285561, encodeId=f8f028556102, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:04 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284415, encodeId=269d284415ca, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:15 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284176, encodeId=f9252841e60d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:30:03 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284173, encodeId=07742841e317, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:28:54 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-02 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=286862, encodeId=abfe28686268, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:53 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285561, encodeId=f8f028556102, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:04 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284415, encodeId=269d284415ca, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:15 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284176, encodeId=f9252841e60d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:30:03 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284173, encodeId=07742841e317, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:28:54 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 神功盖世

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=286862, encodeId=abfe28686268, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:53 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285561, encodeId=f8f028556102, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:04 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284415, encodeId=269d284415ca, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:15 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284176, encodeId=f9252841e60d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:30:03 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284173, encodeId=07742841e317, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:28:54 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 sunfeifeiyang

    0

相关资讯

盘点:2017年9月刊Gut研究精选

2017年9月刊Gut研究精选

盘点:2017年11月Gut研究精选

2017年11月Gut研究精选

盘点:2017年10刊Gut研究精选

2017年10刊Gut研究精选

盘点:2017年12月Gut研究精选

2017年12月Gut研究精选

盘点:2018年1月Gut研究精选

2018年1月Gut研究精选

JCC:英夫利西单抗治疗小儿克罗恩病粪便微生物特征及变化

我们已经知道克罗恩病[CD]与肠道微生物失调有关。英夫利昔单抗[IFX]也越来越多地用于治疗小儿CD,然而目前尚不清楚在IFX治疗期间肠道微生物群如何被改变。这项研究的目的是探讨儿童CD患者的粪便微生物群落组成,并评估其在IFX治疗期间的动态变化。

Baidu
map
Baidu
map
Baidu
map